11:25 Ruijun Tian
Clinical Functional Proteomics Applied to Pancreatic Cancer
11:40 Wei Wu
Mass spectrometry-based assay to screen for PTP dysregulation and activation: a case study in metabolic disease management and reversal
11:55 Jun Adachi
Phosphoproteomic subtyping of gastric cancer reveals dynamic transformation with chemotherapy and guides targeted cancer therapy
12:10 Zheng Ser
Chemical Proteomics and Cross-linking Mass Spectrometry for Identification of Protein-protein Interactions of drug-protein interactome
12:25 Junqi Liang
Large-Scale Libraries of Highly Specific Kinase Substrate Peptides for LC/MS-Based Kinome Profiling
Organized by Jun Adachi (National Institutes of Biomedical Innovation, Health and Nutrition, Japan) and Yasushi Ishihama (Kyoto University, Japan)
A variety of modalities have recently emerged in drug development, and in addition to conventional small molecule compounds and antibody drugs, new types of drugs are being developed. Furthermore, these drugs are often used in combination, making it difficult to elucidate their mechanisms of action. In this session, we will discuss to what extent chemical proteomics and pharmacoproteomics research using mass spectrometry can contribute to drug development.
